In recent years, tumor immunotherapy targeting the immune checkpoint molecule programmed cell death protein 1 (PD-1) and its ligand, PD-L1, has significantly revolutionized the clinical management of various cancers. This evidence concerns the gene PDCD1 and neoplasm.